AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
3
Claroty veterans launch Twine with $12M in Seed funding from Dell and Wiz founders to deploy AI cyber workers
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Prompt Security raises $18 million Series A to protect enterprises from GenAI risks
More news

Bonus Biogroup

5 stories about Bonus Biogroup
ד"ר תומר ברונשטיין סמנכ"ל חדשנות ופיתוח תאגידי בבונוס ביוגרופ

Biotech 2024: Opportunities and challenges for Israeli companies

22.01.24|Tomer Bronshtein
“Despite their strong clinical data and established R&D programs, Israeli biotech companies are undervalued. Following two years of economic downturn, these companies now present attractive investment opportunities,” writes Dr. Tomer Bronshtein, VP for Innovation and Corporate Development at Bonus Biogroup
יוסי כהן ראש המוסד

CTech’s Monday Israeli Tech News Roundup

12.03.18|CTech
Mossad’s venture arm selects startups for its secretive portfolio. The city of Haifa is launching a digital health complex
default image

Company that Develops Injectable Bone Grafts Expands Clinical Trial

12.03.18|Dror Reich
Unlike conventional methods, Bonus Biogroup turns fat tissue collected from patients into bone grafts that can be transplanted with a minimally invasive procedure
בורסה בורסת תל אביב

CTech’s Daily Israeli Tech News Roundup

21.12.17|CTech
Blockchain loses magic hold on Tel Aviv investors. Activists out to change Israel's arm exports policies. The world’s first commercial-scale wave power plant will be built by Israel-based Yam Pro Energy in Ghana. Injectable bone grafts were demonstrated for the first time
default image

Bonus Biogroup Says First Lab-Grown Leg Bone Transplanted in Patient

21.12.17|Lilach Baumer
The Israel-based company's injectable bone grafts are made from fat cells taken from the patients to negate the risk of tissue rejection